A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Phase 2
182
about 5 years
18–65
9 sites in CA, CO, FL +5
About this study
Researchers are testing whether a new ocrelizumab formulation is the same as the existing one when given under the skin. The trial will involve two phases: a controlled phase where participants receive either the new or existing formulation, and a continuation phase where all participants receive the new formulation.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ocrelizumab Reference Formulation
- 2.Take Ocrelizumab Test Formulation
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
injection (Injection)
Primary: Maximum Serum Concentration (Cmax) of Ocrelizumab
Secondary: Number of Participants With Adverse Events (AEs)
Neurology